Blocking an enzyme called PRMT5 may offer a new approach for treating GBM
According to a recent study published in the journal Oncogene, a new strategy for treating glioblastoma (GBM) may be blocking an enzyme called PRMT5 in tumor cells. PRMT5, which is shorthand for protein arginine methyltransferase 5, regulates gene transcription and other cell processes.
Researchers at The Ohio State University Comprehensive Cancer Center demonstrated that knocking down PRMT5 might force cells to slow or stop tumor growth. Developing PRMT5 inhibitors may be a promising therapeutic approach for patients with GBM.